Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €6.02 EUR
Change Today +0.18 / 3.08%
Volume 91.0K
As of 11:35 AM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

integragen (ALINT) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/22/15 - €9.68
52 Week Low
10/16/14 - €4.11
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INTEGRAGEN (ALINT)

Related News

No related news articles were found.

integragen (ALINT) Related Businessweek News

No Related Businessweek News Found

integragen (ALINT) Details

IntegraGen S.A., a biotechnology company, focuses on the development and commercialization of molecular diagnostic tests in France. The company develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes, and obesity. It offers DNA extraction, sample management, and storage services; NextGen sequencing services; SNP genotyping services; and methylation analysis, including DNA sample reception and QC, bisulfite conversion, genotyping analysis, data quality control, delivery of methylation value, and delivery of genome studio project file for data analysis with genome studio software. The company was founded in 2000 and is headquartered in Evry, France.

35 Employees
Last Reported Date: 05/4/15
Founded in 2000

integragen (ALINT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

integragen (ALINT) Key Developments

IntegraGen S.A. Reports Earnings Results for the First Half Ended June 30, 2015

IntegraGen S.A. reported earnings results for the first half ended June 30, 2015. For the period, the company reported total revenues of EUR 2,678,845,000 compared to EUR 2,616,584,000 a year ago. in 2014. This growth was limited by the amount of samples received in first quarter. LBIT was EUR 1,343,453,000 compared to EUR 997,393,000 a year ago. Net loss was EUR 871,966,000 compared to EUR 746,095,000 a year ago. Operating income decreased by EUR 347,000 due to spending for further development of bioinformatics and oncology.

IntegraGen S.A. Presents at Second French Life Science Days Conference, Jun-17-2015

IntegraGen S.A. Presents at Second French Life Science Days Conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.

Integragen Presents Results of Two Studies with New Positive Data on the Role of Microrna Biomarker miR-31-3p in Patients with Metastatic Colorectal Cancer

IntegraGen announced the presentation of two studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting focusing on the association between miR-31-3p expression and clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with panitumumab or cetuximab. The data presented further validates previous studies which have documented that miR-31-3p expression in the primary tumor of mCRC patients is predictive of the effect of anti-EGFR therapy. Study analyzed miR-31-3p expression and associated outcomes in nearly 200 advanced colorectal cancer (aCRC) patients randomized to receive irinotecan or irinotecan plus panitumumab. Patients with lower miR-31-3p expression had significantly better overall and progression free survival (PFS). Patients with lower miR-31-3p expression had significantly better tumor response to panitumumab as measured by response rate and disease control. Patients with low and intermediate miR-31-3p expression had significant PFS benefit from panitumumab while patients with high expression did not. The present study evaluated if miR-31-3p and c-Met expression were associated with the more rapid disease progression seen with cetuximab in the New EPOC study. Expression of miR-31-3p and c-Met in primary tumor and matching CLRM were correlated in patients receiving chemotherapy alone (CT) but not in patients exposed to chemotherapy plus cetuximab (CTC). Study identified a subgroup of patients who derived significant benefit from cetuximab therapy. The loss of correlation between primary tumors and CRLM suggests that cetuximab may modulate miR-31-3p and c-Met expression and that these may be implicated in the mechanism by which earlier progression occurred in these patients.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALINT:FP €6.02 EUR +0.18

ALINT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALINT.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALINT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.2x
Price/Book 6.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTEGRAGEN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at